secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2023-02-21T23:59:59+00:00
Accession:  0001104659-23-023768
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex appoints Rita Jain, M.D. to Board of Directors
------------------------------------------------------

- Rita Jain, M.D. appointed to Celldex Board effective February 16, 2023.
- Dr. Jain receives initial option grant for 17,100 shares vesting over three years.
- She previously served as CMO of ChemoCentryx and Immunovant, and SVP/CMO at Akebia.
- Dr. Jain currently serves on boards of Provention Bio and AM Pharma supervisory board.
- Appointment fills board vacancy; no family relationships or material transactions disclosed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465923023768/0001104659-23-023768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465923023768/tm237425d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-023768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer